Acta oncologica (Stockholm, Sweden) · 2004
Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hasselblom Sverker, Ridell Börje, Wedel Hans, Norrby Klas, Sender Baum Monica, Ekman Tor
Аннотация
From a population-based registry, 35 patients with histologically verified testicular lymphomas were identified: diffuse large B-cell lymphomas (DLBCL) in 33 and peripheral T-cell lymphomas in two cases. Twenty-two patients had localized disease (Pe stage I and II). Twenty-eight patients received systemic chemotherapy, 17 of whom also received intrathecal prophylaxis, and 12 out of these 17 also received radiotherapy to the contralateral testis. In the Pe stage I/II group, 7 out of 21 patients in complete remission (CR) relapsed. In 5 of them the CNS was involved (isolated CNS relapse in three). Remarkably late relapses occurred (up to 127 months). Intrathecal prophylaxis seemed to reduce the frequency of relapses involving the CNS, but the relatively short follow-up (median 45 months, range 34-88, for censored patients) prevents firm conclusions regarding efficacy. The outcome for the stage IV patients was poor, with only 1 out of 11 patients in continuous CR. Immunohistochemical analysis of the DLBCL tumours revealed that 31% had the germinal centre B-cell-like phenotype. CD44 was expressed in all the tumours of stage IV patients but in less than half of the Pe stage I/II patients. A high intratumoural microvessel density was correlated with a high degree of Ki-67 positive tumour cells and an inferior overall survival.
Предметные рубрики MeSH
AdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleCause of DeathFollow-Up StudiesHumansImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingProbabilityProportional Hazards ModelsRadiotherapy, High-EnergyRegistriesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurvival AnalysisTesticular NeoplasmsTreatment Outcome